INMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
INmune Bio Inc (INMB) is not a strong buy at this time for a beginner, long-term investor with $50,000-$100,000 available. The technical indicators are bearish, and the financial performance is weak, with significant YoY declines in net income and EPS. While there are positive catalysts related to FDA feedback and potential global partnerships for Alzheimer's treatment, the lack of strong trading signals, poor financials, and neutral sentiment from insiders and hedge funds suggest holding off on investment until further positive developments or stronger signals emerge.
The technical indicators for INMB are bearish. The MACD histogram is below 0 and negatively contracting, the RSI is neutral at 41.395, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 1.238 and resistance at 1.59.
FDA feedback to advance XPro1595 to a registrational study for Alzheimer's treatment and the potential for global partnerships to enhance clinical and commercial potential.
Weak financial performance with significant YoY declines in net income (-46.48%) and EPS (-60.00%). Bearish technical indicators and lack of significant trading trends from insiders or hedge funds.
In Q3 2025, revenue remained at 0 with no growth YoY. Net income dropped by -46.48% YoY to -$6.47M, and EPS declined by -60.00% YoY to -0.24. Gross margin remained at 100% with no change YoY.
No data available for analyst ratings or price target changes.
